Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2018 / Cilt: 28 - Sayı: 3

Effect of pegylated interferon and ribavirin on metabolic factors and triglyceride index in chronic hepatitis C patients

Kronik hepatit C hastalarında pegile-interferon ve ribavirin tedavisinin trigliserit indeks ve metabolik faktörler üzerine etkisi

Pages
155–162
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is a need for prospective studies investigat- ing the reliability of the TyG index in hepatitis C patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The study aimed to investigate the influence of ribavirin and pegylated interferon alfa 2a/2b combination therapy on metabolic factors and triglyceride index in chronic hepatitis C patients.
📊
Key Findings & Data:Method: A total of 165 chronic hepatitis C patients aged between 20 and 75 years with available uric acid and HCV-RNA levels examined at 0, 12, 24., 48., and 72. weeks and admitted to Gastroenterology Department of Atatürk Training and Research Hospital, Katip Çelebi University between January 2005 and January 2012 were enrolled.
💡
Conclusion & Impact:There is a need for prospective studies investigat- ing the reliability of the TyG index in hepatitis C patients.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The study aimed to investigate the influence of ribavirin and pegylated interferon alfa 2a/2b combination therapy on metabolic factors and triglyceride index in chronic hepatitis C patients. Method: A total of 165 chronic hepatitis C patients aged between 20 and 75 years with available uric acid and HCV-RNA levels examined at 0, 12, 24., 48., and 72. weeks and admitted to Gastroenterology Department of Atatürk Training and Research Hospital, Katip Çelebi University between January 2005 and January 2012 were enrolled. Patients were divided into groups based on therapy response (sustained viralresponse, relapse, and nonresponders) and the levels of the parameters were evaluated. Results: All patients enrolled in our study were included in our investigation. SVR was achieved in 91 of 165 patients. HCV-RNA levels in patients without sustained viral response were higher than those without. In univariate analyzes, a significant relationship was found between age, 72 hour- HOMA score, platelet counts and log 10 HCV-RNA in patients with and without sustained viral response.In univariate analyzes a significant difference could not found between HOMA scors, and TyG levels. In mutivariate analyzes a significant difference was not found between HOMA scores, and TyG index values, and their impact on treatment was not observed. Conclusion: There is a significant correlation between HOMA score and TyG index in patients with hepatitis C according to our study results. Any correlation could not be found between the TyG index levels and the treatment response. There is a need for prospective studies investigat- ing the reliability of the TyG index in hepatitis C patients.

Özet

Amaç: Kronik hepatit C olgularının tedavisinde kullanılmakta olan pegile interferon alfa (PEGIFN-a) 2a/2b ve ribavirin tedavisinin trigliserit indeks ve metabolik faktörler üzerine etkisinin incelenmesi amaçlandı. Yöntem: Çalışmaya 01.01.2005 ile 01.11.2012 tarihleri arasında Katip Çelebi Üniversitesi Tıp Fakültesi Atatürk Eğitim Araştırma Hastanesi Gastroenteroloji Polikliniğinde kronik hepatit C tanısı alan, tedavi öncesi ve tedavi sırasında serum ürik asit ve HCV-RNA (0., 12., 24., 48. ve 72. hafta) düzeyleri bakılan, yaşları 20 ile 75 arasında değişen toplam 165 hasta dahil edilmiştir. Tedavi yanıtına göre (kalıcı viral yanıt, relaps ve non-responder-yanıtsız) bu parametrelerin düzeyleri değerlendirilmiştir. Bulgular: Çalışmamıza alınan 165 hastanın tamamı çalışmaya dahil edildi. Dahil edilen 165 hastanın 91’inde kalıcı viral yanıt (SVR) alındı, 74’ünde ise kalıcı viral yanıt alınamadı (non SVR). Kalıcı viral yanıt alınmayan hastaların HCV-RNA düzeyleri kalıcı viral yanıt alınan has- talara göre yüksekti. Tek değişkenli analizlerde kalıcı viral yanıt alınan ve alınmayan hastalarla yaş, 72.saat HOMA skoru, trombosit ve log 10 HCV-RNA arasında anlamlı bir ilişki saptandı. Kalıcı viral yanıt alınan hastalar ile alınmayan hastalar arasında tek değişkenli verilerde hem HOMA skoru hem de TyG indeks değerleri arasında anlamlı fark saptanmadı. Çok değişkenli analiz uygulandığında da hem HOMA skoru hem de TyG indeks değerleri arasında anlamlı fark saptanmadı ve tedaviye etkisinin olmadığı gözlendi. Sonuç: Çalışmamıza göre hepatit C hastalarında HOMA skoruyla TyG indeksi arasında anlamlı korelasyon mevcuttur. TyG indeks düzeyleriyle tedaviye yanıt arasında ise ilişki bulunmamıştır. TyG indeksinin hepatit C hastalarında güvenilirliğini araştıran prospektif çalışmalara gereksi- nim vardır.

🔖

Cite This Article

KOYUNCU, B., ALTIN, Z., ÖZER, S., ASLAN, F., ÜNSAL, B. (2018). Effect of pegylated interferon and ribavirin on metabolic factors and triglyceride index in chronic hepatitis C patients. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 28 - Sayı: 3, 155–162. https://ajindex.com/articles/199213

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Marcellin P. Management of Patients with Viral Hepatitis, 2007
  2. APHC, Paris France. Akhan S. Hepatit C virüsü. Topçu AW, Söyletir G, Doğanay M (editörler). İnfeksiyon Hastalıkları ve Mikrobiyolojisi. İstanbul: Nobel Tıp Kitabevleri, 2008:1911-29. Consensus conference. Treatment of hepatitis C. Guidelines. Gastroenterol Clin Biol. 2002;26:B312-B320. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virüs infection. N Engl J Med. 2002;347:975-82. https://doi.org/10.1056/NEJMoa020047
  3. Cornberg M, Manns MP, Wedemeyer H, Hepatitis C. Standard of care. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (eds). Hepatology, A Clinical Textbook. Germany: Flying Publisher, 2009:183-98.
  4. Grace MJ, Bordens RW, Cutler DL. Peginterferons for the treatment of chronic hepatitis C. Hepatology Rev. 2005;2:3-9.
  5. Aspinall RJ, Pockros PJ. Review article: The management of side effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20:917-29. https://doi.org/10.1111/j.1365-2036.2004.02192.x Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1):237-44.
  6. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol. 2011 Dec;55(6):1187-94. https://doi.org/10.1016/j.jhep.2011.03.010
  7. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O’Rahilly S, Shore S, Tom BD, Alexander GJ. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999 Oct;30(4):105963. https://doi.org/10.1002/hep.510300416
  8. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int. 2009 Mar;29(Suppl 2):26-37. https://doi.org/10.1111/j.1478-3231.2008.01950.x Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, FernándezRodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005 Mar;128(3):636-41. https://doi.org/10.1053/j.gastro.2004.12.049
  9. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Swiss Hepatitis C Cohort Study. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol. 2005 Jan;42(1)